Around 70% of metastatic and nodular malignant melanomas (NMM) - as well as 50% of superficial spreading melanomas (SSM) - showed strong CPI-17 expression, compared to only 20% of benign nevi samples (Table 1). This evidence concerns the gene PPP1R14A and nodular malignant melanoma.